Engineered Platelets: A Synthetic Biology Approach To Combat Cancer Metastasis

Engineered platelets are being developed as a novel therapeutic strategy to target and destroy circulating tumor cells (CTCs), potentially preventing cancer metastasis.

Metastasis, primarily driven by CTCs, is the leading cause of cancer mortality, and current therapies are insufficient in preventing the spread of these cells.

This technology leverages synthetic biology to engineer platelets that can deliver bioactive proteins specifically to CTCs. By utilizing genetic circuits and stem cell differentiation, platelets are loaded with split toxins conjugated to synthetic monoclonal antibodies targeting overexpressed receptors on CTCs. These engineered platelets are designed to release their payload upon encountering CTCs, thereby selectively destroying them without harming other cells, reducing the risk of metastasis.

Proof of Concept

• Targeted Therapy: Engineered platelets deliver toxins directly to CTCs, minimizing systemic toxicity.
• Precision Medicine: The use of synthetic monoclonal antibodies allows for the specific targeting of cancer cells.
• Advanced Engineering: Genetic switching networks control the differentiation and loading of bioactive proteins in platelets.
• Potential for Wide Application: This platform could be adapted to target various types of cancer cells, offering a versatile approach to cancer therapy.

Javdan SB, Islam F, Deans TL. Reprogramming megakaryocytes to engineer platelets as delivery vehicles. Preprint. bioRxiv. 2023;2023.10.13.562311. Published 2023 Oct 14. doi:10.1101/2023.10.13.562311

Jason Young
(801) 587-0519
jason.r.young@utah.edu